| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 08/14/2013 | CN101128478B N protein mutants of porcine reproductive and respiratory syndrome virus |
| 08/14/2013 | CN101068836B Anti-glypican 3 antibody having modified sugar chain |
| 08/13/2013 | US8507748 Method for the production of a single heavy chain antibody |
| 08/13/2013 | US8507658 Ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in the method |
| 08/13/2013 | US8507442 Methods of use for an antibody against human frizzled receptors 1, 2. 5, 7 or 8 |
| 08/13/2013 | US8507249 Bacterial virulence factors and uses thereof |
| 08/13/2013 | US8507238 Polypeptides having cellobiohydrolase 1 activity and polynucleotides encoding same |
| 08/13/2013 | US8507212 Process for in vivo treatment of specific biological targets in bodily fluids |
| 08/13/2013 | US8507196 Nucleic acid probe of human immunodeficiency virus type 1 (HIV-1), and a method and kit employing this probe for detecting the presence of nucleic acid of HIV-1 |
| 08/13/2013 | US8506971 Method for adjuvanting lipopolysaccharide (LPS) of gram-negative bacteria |
| 08/13/2013 | US8506970 Dose and localization of botulinum toxins in skin and muscle |
| 08/13/2013 | US8506969 Efficient cell culture system for hepatitis C virus genotype 7a |
| 08/13/2013 | US8506968 SARS vaccine compositions and methods of making and using them |
| 08/13/2013 | US8506967 Functional influenza virus like particles (VLPs) |
| 08/13/2013 | US8506966 Adjuvanted influenza vaccines for pediatric use |
| 08/13/2013 | US8506965 R-RAS activity in vascular regulation |
| 08/13/2013 | US8506964 Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis |
| 08/13/2013 | US8506963 Anti-EFGRv3 monoclonal antibody |
| 08/13/2013 | US8506962 Sustained release drug delivery systems comprising a water soluble therapeutic agent and a release modifier |
| 08/13/2013 | US8506961 Humanized monoclonal antibodies that specifically bind and/or neutralize japanese encephalitis virus (JEV) and their use |
| 08/13/2013 | US8506960 Antibody molecule for human GM-CSF receptor alpha |
| 08/13/2013 | US8506959 Prevention and treatment of synucleinopathic and amyloidogenic disease |
| 08/13/2013 | US8506958 Methods for treating TWEAK-related conditions |
| 08/13/2013 | US8506957 Methods and compositions for monitoring progression of huntington's disease |
| 08/13/2013 | US8506954 Tumor vaccination in combination with hematopoietic cell transplantation for cancer therapy |
| 08/13/2013 | US8506949 Methods for modulating inflammatory and/or immune responses |
| 08/13/2013 | CA2655138C Compositions comprising chitin microparticles and their medical uses |
| 08/13/2013 | CA2564674C Drying process for preserving an active agent as a highly viscous liquid |
| 08/13/2013 | CA2562784C Fluorocarbon antigen delivery vectors and constructs |
| 08/13/2013 | CA2529941C Method for identification of tr1 lymphocytes regulators by the presence and overexpression of specific molecules and application thereof |
| 08/13/2013 | CA2529647C Influenza hemagglutinin and neuraminidase variants |
| 08/13/2013 | CA2517673C Improved vaccines for preventing viral infection |
| 08/13/2013 | CA2482930C Epha2 antigen t epitopes |
| 08/13/2013 | CA2477236C Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders |
| 08/13/2013 | CA2464138C Methods of preventing and treating flavivirus infection in animals |
| 08/13/2013 | CA2438513C Modified anti-egfr antibodies with reduced immunogenicity |
| 08/13/2013 | CA2433316C Molecular antigen array |
| 08/13/2013 | CA2413003C Immunoassays for anti-hcv antibodies |
| 08/13/2013 | CA2371928C Neisserial vaccine compositions and methods |
| 08/13/2013 | CA2314319C Novel surface protein of neisseria meningitidis |
| 08/13/2013 | CA2304932C Recombinant rsv virus expression systems and vaccines |
| 08/13/2013 | CA2258277C Characterization of granulocytic ehrlichia and methods of use |
| 08/13/2013 | CA2222643C Lawsonia intracellularis cultivation, anti-lawsonia intracellularis vaccines and diagnostic agents |
| 08/08/2013 | WO2013116822A1 Methods and compositions for treating gastric disorders |
| 08/08/2013 | WO2013116770A1 Replication-defective flavivirus vaccines and vaccine vectors |
| 08/08/2013 | WO2013116686A1 Methods and products related to targeted cancer therapy |
| 08/08/2013 | WO2013116668A2 Diagnostic peptides for lyme disease |
| 08/08/2013 | WO2013116656A1 Immunostimulatory compositions, particles, and uses related thereto |
| 08/08/2013 | WO2013116639A1 Campylobacter immunogenic compositions and uses thereof |
| 08/08/2013 | WO2013116591A1 Adenoviral vector-based malaria vaccine |
| 08/08/2013 | WO2013116590A1 Inhibition of pattern recognition receptors in pancreatic cancer treatment using tlr inhibitors |
| 08/08/2013 | WO2013116296A1 Anti-asic1 antibodies and uses thereof |
| 08/08/2013 | WO2013114885A1 Human monoclonal antibodies broadly protective against influenza b virus and methods of using the same |
| 08/08/2013 | WO2013114339A1 Combination therapy for cancer using hsp27 inhibitor and egfr tyrosine kinase inhibitors or anti-folates |
| 08/08/2013 | WO2013114268A1 Immunogenic composition |
| 08/08/2013 | WO2013114245A1 Process of modulating man5 and/or afucosylation content of glycoprotein composition |
| 08/08/2013 | WO2013114167A1 Process of obtaining glycoform composition |
| 08/08/2013 | WO2013114112A2 Stabilized aqueous antibody compositions |
| 08/08/2013 | WO2013113865A1 Eimeria vector vaccine for campylobacter jejuni |
| 08/08/2013 | WO2013113820A1 Antibody-containing sustained-release formulation for ocular administration |
| 08/08/2013 | WO2013113774A1 Factor xii inhibitors for the treatment of neurological inflammatory disorders |
| 08/08/2013 | WO2013113729A1 Fermentation process |
| 08/08/2013 | WO2013113641A1 Use of nkp46 as a predictive biomarker for cancer treatment with adcc- enhanced antibodies |
| 08/08/2013 | WO2013113502A1 Negatively charged nucleic acid comprising complexes for immunostimulation |
| 08/08/2013 | WO2013113501A1 Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or pepide antigen |
| 08/08/2013 | WO2013113326A1 Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| 08/08/2013 | WO2013113325A1 Negatively charged nucleic acid comprising complexes for immunostimulation |
| 08/08/2013 | WO2013113107A1 Methods for promoting neuron survival, axonal growth and/or regeneration |
| 08/08/2013 | WO2013113092A1 Methods of determining cell mediated response |
| 08/08/2013 | WO2013090965A3 Composition containing antibodies against gluten and tannins |
| 08/08/2013 | WO2013086052A3 Antibodies useful in passive influenza immunization |
| 08/08/2013 | WO2013084070A3 Salmonella vaccine proteins |
| 08/08/2013 | WO2013082298A3 Immunological composition for clostridium difficile |
| 08/08/2013 | WO2013071038A3 Antagonists for abnormal vasopressin v2 receptor and uses thereof |
| 08/08/2013 | WO2012079093A3 Dosage and administration of bispecific scfv conjugates |
| 08/08/2013 | US20130204069 Compositions and Methods of Treating Tumors |
| 08/08/2013 | US20130203961 Molecular Vaccine Linking an Endoplasmic Reticulum Chaperone Polypeptide to an Antigen |
| 08/08/2013 | US20130203682 Rank ligand polypeptides |
| 08/08/2013 | US20130202708 Viral particle released after infection of mammalian cells by human cytomegalovirus (hcmv) containing a fusion protein and use thereof |
| 08/08/2013 | US20130202707 Controlled Delivery of TLR Agonists in Structural Polymeric Devices |
| 08/08/2013 | US20130202680 Prevention and treatment of alzheimer's disease by amyloid beta peptide and sphin-gosine-1-phosphate |
| 08/08/2013 | US20130202655 Vaccines, Methods of Administering Vaccines, Methods and Products for Treating and/or Delaying Onset of Dysplastic Lesions, and Wafers for Oral Administration |
| 08/08/2013 | US20130202645 Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
| 08/08/2013 | US20130202643 Avirulent Salmonella Gallinarum Variants and Pharmaceutical Composition Using the Same |
| 08/08/2013 | US20130202642 Immunogenic compositions against tuberculosis |
| 08/08/2013 | US20130202641 Immunology treatment for biofilms |
| 08/08/2013 | US20130202640 Compositions and methods for vaccinating against hsv-2 |
| 08/08/2013 | US20130202638 Vaccine against beta-herpesvirus infection and use thereof |
| 08/08/2013 | US20130202636 Compositions and Methods for Topical Application and Transdermal Delivery of Botulinum Toxins |
| 08/08/2013 | US20130202635 Peptide vaccines against group a streptococci |
| 08/08/2013 | US20130202632 Minimal motifs of linear b-cell epitopes in l1 protein from human papillomavirus type 58 and their applications |
| 08/08/2013 | US20130202630 Compositions and methods for enhancing immune responses to vaccines |
| 08/08/2013 | US20130202629 Uses of phospholipid conjugates of synthetic tlr7 agonists |
| 08/08/2013 | US20130202627 Use of flagellins from the genus marinobacter as vaccination adjuvants |
| 08/08/2013 | US20130202624 Human b1 cells and uses thereof |
| 08/08/2013 | US20130202623 Pd-1 modulation and uses thereof for modulating hiv replication |
| 08/08/2013 | US20130202619 Methods and materials for reducing liver fibrosis |
| 08/08/2013 | US20130202618 Antibodies for the treatment of clostridium difficile-associated infection and disease |
| 08/08/2013 | US20130202615 Anti-vegf antibodies and uses thereof |
| 08/08/2013 | US20130202614 Autotaxin pathway modulation and uses thereof |